title: Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer.
abstract: In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent "split-course" chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5% objective responses (OR) with 52.5% complete responses (CR), a median survival of 14 months, with 13% long-term survivors at 30 months. In extensive disease we obtained 83.6% OR with 28.5% CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.
authors.affiliation: Cattedra di Oncologia Medica, II Fac. Med. e Chir., Università di Napoli, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Gridelli
authors.forename: G P
authors.initials: GP
authors.lastname: Ianniello
authors.forename: A
authors.initials: A
authors.lastname: Maiorino
authors.forename: C
authors.initials: C
authors.lastname: Curcio
authors.forename: M
authors.initials: M
authors.lastname: D'Aprile
authors.forename: L
authors.initials: L
authors.lastname: Brancaccio
authors.forename: S
authors.initials: S
authors.lastname: Palmeri
authors.forename: M
authors.initials: M
authors.lastname: Gentile
authors.forename: G
authors.initials: G
authors.lastname: Comella
authors.forename: T
authors.initials: T
authors.lastname: Pedicini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D015251:Epirubicin; D005047:Etoposide; D016190:Carboplatin